Tags : Palatin Technologies

Palatin Technologies’ Vyleesi (bremelanotide injection) Receives FDA’s Approval for Premenopausal

Shots: Vyleesi (SC) is a pre-filled autoinjector pen used in anticipation of a sexual encounter melanocortin receptor agonist, approved for premenopausal women experiencing distress or interpersonal difficulty due to low sexual desire In 2017, Palatin signed an agreement with AMAG pharmaceuticals for commercialization of Vyleesi. Palatin to receive $60M on FDA’s approval with milestones based […]Read More